Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
LifespanningRx's partnership with RegenTherapy expands access to regenerative longevity programs by integrating cellular recovery technologies into a consumer-friendly telehealth platform. The collaboration reflects a shift in regenerative medicine from elite-only treatments toward mainstream accessibility, positioning cellular signaling support as infrastructure for sustained functional health rather than life extension.
Continuous hormonal monitoring via wearable technology addresses a fundamental gap in women's healthcare: annual or biannual blood tests cannot capture hormonal dynamics that fluctuate hourly and respond to immediate environmental and physiological pressures. This shift from static snapshots to real-time signal interpretation reframes how women's health is understood and managed.
Rigorous problem definition forms the foundation for rational medication and supplement selection. Without clear diagnostic criteria and measurable outcomes, interventions risk generating false positives that obscure rather than clarify individual health status.
An educational intervention combining aging awareness training with structured contact experiences significantly reduced ageist attitudes among healthcare providers in a quasi-experimental design. This finding addresses a critical gap in clinical practice: provider bias directly shapes clinical decision-making, diagnostic thoroughness, and treatment escalation in older patients.
Osteocalcin, a bone-derived hormone, activates protective mechanisms in the nervous system when estrogen declines following ovariectomy in mice. This finding identifies a compensatory endocrine pathway that may explain neurological resilience during menopause and suggests osteocalcin as a therapeutic target for estrogen-deficiency-related cognitive decline.
Oligomerix completed a Phase 1a trial of OLX-07010, an oral tau-targeting therapy showing favorable safety and appropriate drug exposure in healthy volunteers. The compound represents a shift toward preventive approaches in neurodegeneration by inhibiting tau protein misfolding rather than clearing existing damage.
Cognition Therapeutics has aligned with the FDA on a regulatory pathway for zervimesine (CT1812), an oral therapeutic showing efficacy in Phase 2 trials for dementia with Lewy bodies complicated by psychosis. This represents meaningful progress toward a registrational study for a condition with limited treatment options and significant cognitive and neuropsychiatric burden.
Researchers developed a multimodal ocular aging index using protein signatures that predicts age-related eye disease onset years before clinical symptoms appear. The index identifies specific proteomic pathways underlying macular degeneration and other vision conditions, enabling earlier intervention before irreversible damage occurs.
Effective disease-modifying therapies for Alzheimer's disease are forcing a diagnostic infrastructure shift from academic research to scalable clinical detection. Early identification now determines treatment efficacy, requiring systems that can identify pathology years before cognitive symptoms emerge.
Nourish, an AI-assisted nutrition clinic, secured $100 million in Series C funding to scale a model treating chronic disease through behavior change and dietitian-led care rather than medication alone. The company addresses a critical gap in healthcare: chronic conditions develop through years of metabolic drift, yet most interventions remain reactive rather than preventive, with behavioral sustainability determining long-term outcomes.
Beacon Biosignals demonstrates that at-home EEG monitoring paired with machine learning can detect sleep arousals with accuracy matching expert human raters, even in complex populations taking antidepressants. This advances sleep as a quantifiable biomarker for brain health and depression research without the confounding effects of laboratory environments.
A UCL study reported associations between arts engagement and slower biological aging, but the research lacks rigorous causal design. The findings cannot distinguish whether arts participation slows aging, whether poor health limits participation, or whether socioeconomic factors and lifestyle differences account for the observed patterns.